BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Develops First-Ever Effective Treatment for Root-Rot Disease

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide is 100% effective against root-rot disease. This announcement followed a recent round of laboratory tests, “which were conducted by an independent third-party lab,” an article on MustGrow’s novel accomplishment details. MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, becomes the first to develop an effective treatment for this disease. The “patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates… Aphanomyces is a soil-borne, root-rot disease that destroys peas, lentils and legume crops, commonly referred to as pulse crops. In infected fields, the disease can result in yield losses ranging from 10% to 100% complete destruction… Currently the only available treatments slow down the spread in an attempt to reduce the severity of the disease; no treatments exist that control the devastating root-rot plague. MustGrow’s plant-based biopesticide aims to change that.”

To view the full article, visit https://ibn.fm/irMWy

About MustGrow Biologics Corp

MustGrow is a publicly traded agriculture biotech company focused on providing natural science-based biological solutions for high-value crops, including fruits and vegetables. MustGrow has designed and owns a United States EPA-approved natural solution that uses the mustard seed’s natural defense mechanism to protect plants from pests and diseases. Over 110 independent tests have been completed, validating MustGrow’s safe and effective signature products. The product, in granule format, is EPA-approved across all key U.S. states and by Health Canada’s PMRA (Pest Management Regulatory Agency) as a bio-pesticide for high-value crops such as fruit and vegetables. MustGrow has now concentrated a liquid format, TerraMG, which, with regulatory approval, could be applied through standard drip or spray equipment, improving functionality and performance features. For more information, visit the company’s website at www.MustGrow.ca.

NOTE TO INVESTORS: The latest news and updates relating to MGROF are available in the company’s newsroom at https://ibn.fm/MGROF

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

2 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting 

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026,…

2 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) 

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult…

3 days ago

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Issues Shareholder Letter Outlining Strategic Review and Focus on TPI 287

CNS Pharmaceuticals (NASDAQ: CNSP) released a Letter to Shareholders from newly appointed President and Chief…

5 days ago

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Engages IBN for Corporate Communications Support

Earth Science Tech (OTC: ETST), a strategic holding company advancing a portfolio of operating businesses…

1 week ago

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Appoints Bryan Humbarger as Chief Commercial Officer 

HeartBeam (NASDAQ: BEAT), a medical technology company focused on advancing cardiac care through actionable cardiac insights,…

1 week ago